Dihydroisoxazole Analogs for Labeling and Visualization of Catalytically Active Transglutaminase 2  by Dafik, Laila & Khosla, Chaitan
Chemistry & Biology
ArticleDihydroisoxazole Analogs for Labeling
and Visualization of Catalytically Active
Transglutaminase 2
Laila Dafik1 and Chaitan Khosla1,2,*
1Departments of Chemistry and Chemical Engineering
2Department of Biochemistry
Stanford University, Stanford, CA 94305, USA
*Correspondence: khosla@stanford.edu
DOI 10.1016/j.chembiol.2010.11.004SUMMARY
We report the synthesis and preliminary character-
ization of ‘‘clickable’’ inhibitors of human transgluta-
minase 2 (TG2). These inhibitors possess the
3-halo-4,5-dihydroisoxazole warhead along with
bioorthogonal groups such as azide or alkyne moie-
ties that enable subsequent covalent modification
with fluorophores. Their mechanism for inhibition of
TG2 is based on halide displacement, resulting in
the formation of a stable imino thioether. Inhibition
assays against recombinant human TG2 revealed
that some of the clickable inhibitors prepared in
this study have comparable specificity as benchmark
dihydroisoxazole inhibitors reported earlier. At low
micromolar concentrations they completely inhibited
transiently activated TG2 in a WI-38 fibroblast
scratch assay and could subsequently be used to
visualize the active enzyme in situ. The potential
use of these inhibitors to probe the role of TG2 in
celiac sprue as well as other diseases is discussed.
INTRODUCTION
Mammalian transglutaminases play important roles in many
biological processes such as blood clotting, wound healing,
extracellular matrix formation, and cell adhesion and motility
(Akimov and Belkin, 2001; Fesus et al., 1987; Iismaa et al.,
2009; Lorand, 2007; Lorand and Graham, 2003; Piacentini
et al., 1991; Zemskov et al., 2006). Transglutaminase 2 (TG2),
a ubiquitous member of this enzyme family, is found in intracel-
lular as well as extracellular environments of many organs. In the
presence of calcium and the absence of GTP or GDP, TG2
crosslinks selected g-glutaminyl and 3-lysine residues on
proteins, leading to the formation of proteolytically resistant
covalent bonds. This catalytically active form of TG2 exists in
an extended (‘‘open’’) conformation (Pinkas et al., 2007). In
contrast, in the absence of calcium and the presence of GTP
or GDP, TG2 assumes an inactive (‘‘closed’’) form (Liu et al.,
2002) and functions as a G protein in the phospholipase C signal
transduction cascade of the a-adrenergic receptor (Nakaoka58 Chemistry & Biology 18, 58–66, January 28, 2011 ª2011 Elsevieret al., 1994; Singh et al., 1995). TG2 activity is also subject to
regulation by local redox conditions (Stamnaes et al., 2010).
Under oxidizing conditions, the formation of an intramolecular
disulfide bond inactivates the enzyme; activity is reversibly
restored under reducing conditions. Given the ubiquitous nature
of TG2 and its ability to form covalent ‘‘scars,’’ its catalytic
activity must be tightly regulated in mammals. However, the
physiological signals that interconvert these active and inactive
forms of the enzyme remain largely unknown. For example,
whereas the majority of extracellular TG2 in the mouse small
intestine is inactive, it can be rapidly activated at the villus tips
by administration of poly(I:C), a ligand of the TLR-3 innate
immune receptor (Siegel et al., 2008). Therefore, chemical
probes of in vivo TG2 biology should be of considerable use in
resolving some of these fundamental mysteries associated
with allosteric TG2 regulation.
From a translational standpoint, TG2 is implicated in the
pathogenesis of a number of unrelated disorders, including
neurological diseases such as Huntington’s, Alzheimer’s, and
Parkinson’s disease, certain types of cancers and renal
diseases, and celiac sprue (Ruan and Johnson, 2007; Shweke
et al., 2008; Verma and Mehta, 2007). For example, in celiac
sprue, peptides derived from dietary gluten are deamidated by
TG2 to enhance their affinity toward the disease-associated
class II major histocompatibility complexes, which in turn
activates inflammatory Th1 cells (Sollid and Lundin, 2009).
Therefore, TG2 may be a suitable target for celiac sprue therapy.
However, absent knowledge of the location, timing, and mecha-
nism of TG2 activation in the celiac small intestine, this hypoth-
esis cannot be rationally tested. Again, chemical probes could
provide answers to these questions. Last, but not least, small
molecule TG2 inhibitors could also serve as drug leads and even-
tually as drug candidates for one or more of the above diseases
(Siegel and Khosla, 2007).
Many classes of irreversible, active site inhibitors of human
TG2 have been reported thus far (Case et al., 2005;
Choi et al., 2005; Freund et al., 1994; Halim et al., 2007; Hausch
et al., 2003; Keillor, 2005; Pardin et al., 2006, 2008; Schaertl
et al., 2010). One example is the 3-bromo-4,5-dihydroisoxazoles
(DHIs) family of compounds (Castelhano et al., 1988; Choi et al.,
2005; Watts et al., 2006). Guided by the excellent tolerance of
these molecules in acute and chronic administration studies in
rodents (Choi et al., 2005; Yuan et al., 2007), here, we have
used the DHI scaffold to develop a class of covalent TG2 probesLtd All rights reserved
Figure 1. Labeling and Visualization of Catalytically Active (but Not Catalytically Inactive) TG2 with Alkynyl-DHI Inhibitors
Similar labeling strategy can be employed using azido-DHI inhibitors.
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Tools for Visualizing Transglutaminase Activitythat bind to active but not inactive TG2 and can, therefore, be
used to visualize the enzyme via a selective (bioorthogonal)
chemical reaction (Figure 1). Analogous strategies have been
used to modify cell surface glycans and proteins (Chin et al.,
2002; Deiters and Schultz, 2005; Wang and Schultz, 2004), to
profile protein glycosylation (Agard and Bertozzi, 2009), and for
the detection of lipid-modified proteins (Hang et al., 2007).
Recently, bioorthogonal chemical reporters have also been
used in living animals as noninvasive imaging tools (Laughlin
et al., 2008; Laughlin and Bertozzi, 2009; Prescher and Bertozzi,
2005).RESULTS
Design and Synthesis of Azido- and Alkynyl-DHI
Inhibitors
In this study we describe the synthesis and properties of DHI
inhibitors of human TG2 that are conjugated to alkyne or azide
functional groups. We incorporated alkyne and azide groups
because of their bioorthogonality (Sletten and Bertozzi, 2009).
Figure 2describes the structure and synthesis of a representativeFigure 2. General Synthesis of Azido- and Alkynyl-DHI Inhibitors
See Figure S1.
Chemistry & Biology 18,DHI inhibitor. Both azide and alkyne groups were introduced as
substitutions on the carbobenzyloxy (Cbz) moiety because
previous studies had highlighted the advantage of an aromatic
group at this position (Watts et al., 2006). To identify a clickable
inhibitor with optimal activity, we also varied the amino acid
moiety of our DHI inhibitors using side chains that had previously
been found to be beneficial. The compounds synthesized and
evaluated in this study are summarized in Table 1; all of them
were made in good yield and purity (see Supplemental Experi-
mental Procedures and Figure S1 available online). Four
previously synthesized DHI inhibitors, 13–16, were chosen as
reference compounds in this study; their TG2 inhibitory activities
vary over an 8-fold range (Table 1).Inhibition of Recombinant Human TG2
by Azido- and Alkynyl-DHI Inhibitors
The potencies of alkynyl- and azido-DHI inhibitors 1–12 were
evaluated in a kinetic assay using recombinant human TG2. In
this assay, TG2-catalyzed deamidation of the dipeptide
substrate Cbz-Gln-Gly is monitored under steady-state condi-
tions. Analogous to the parameters of the Michaelis-Menten58–66, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 59
Table 1. TG2 Inhibitory Activity of Enantiopure Azido- and Alkynyl-DHI Compounds
Compounds 17 and 18 have a stereochemically altered DHI moiety and are, therefore, considerably less potent than their diastereomeric analogs, 11
and 12, respectively.
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reactivity of the DHI warhead with the active site sulfhydryl of
TG2, whereas Ki estimates the reversible binding affinity of the
inhibitor to the active site. The bimolecular rate constant kinh/Ki
can be thought of as the specificity constant of TG2 for the
inhibitor.
As summarized in Table 1, inhibitors harboring tryptophan
analogs are more potent than those with tyrosine as the amino
acid residue. Among tryptophan analogs, the 5-fluorotryptophan
analogs have the highest specificity constants. The relative
trends are similar between the azido-DHI and alkynyl-DHI inhib-
itor series. The most active alkynyl- and azido-DHI inhibitors (12
and 6, respectively) have specificity constants that are within
1.3- and 2.3-fold, respectively, of the most potent DHI inhibitor
16 identified to date. Together, these results encouraged us to
evaluate some of these compounds in a cell culture assay for
activated TG2.
It is noteworthy that the azido-DHI inhibitors prepared in this
study have moderately higher TG2 specificity (kinh/Ki) than their
alkynyl-DHI counterparts (Table 1). However, this benefit is
primarily derived from higher reactivity toward the active site
cysteine residue of TG2; the reversible binding affinity (Ki) of
the alkynyl-DHI inhibitors is actually higher. Although the reason60 Chemistry & Biology 18, 58–66, January 28, 2011 ª2011 Elsevierfor this inverse correlation between affinity and specificity
remains to be understood, in subsequent studies we placed
greater emphasis on biological evaluations of the most prom-
ising alkynyl-DHI inhibitors.
Inhibition of TG2 in a Tissue Culture Wounding Model
To evaluate the activity of the clickable TG2 inhibitors identified
above in a representative biological assay, we used a tissue
culture wounding model. TG2 plays a role in wound healing in
mammals by crosslinking extracellular matrix proteins after
a wound has been inflicted. Recently, we demonstrated that,
when a confluent monolayer of WI-38 fibroblast cells is
scratched, TG2 is rapidly and transiently activated in the zone
surrounding the ‘‘wound’’ (Siegel et al., 2008). This activated
TG2 enzyme can be visualized using 5-biotinyl pentylamine
(5BP), which presumably crosslinks onto glutamine side chains
of fibronectin and other proteins along the scratch border that
are recognized as TG2 substrates (Figure 3). Here, we have
exploited this assay to compare the relative activities of TG2
inhibitors in a biological system.
To quantify inhibitor potency, selected inhibitors were added
to scratched WI-38 cultures at incremental 2-fold dilutions. The
lowest inhibitor concentration at which complete inhibition ofLtd All rights reserved
Figure 3. Titration of 11 against Active TG2 in a Fibroblast Scratch Assay
TG2 activity was visualized in situ after scratching a confluentWI-38monolayer with a small pipette tip. Significant TG2 activity was detected around the wound in
the presence of 300 mM 5BP and vehicle (DMSO) (A–C). Clear inhibition of active TG2 was observed in the presence of 6.25 mM 11 (G–I), and complete inhibition
was observed at or above 12.5 mM 11 (J–O). In this assay, active TG2 was detected by exposing fixed cultures to streptavidin Alexa Fluor 555 (A, D, G, J, and M).
The scratch geometry is conveniently visualized by co-staining with polyclonal anti-fibronectin antibody, followed by a secondary antibody conjugated Alexa
Fluor 488 (B, E, H, K, and N). Overlays of the left andmiddle images are in the right column (C, F, I, L, and O). Scale bar represents 200 mmand applies to all panels.
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Tools for Visualizing Transglutaminase Activitytransiently activated TG2 was observed was recorded as the
minimum inhibitory concentration (MIC) of that inhibitor. For
example the effect of increasing concentrations of 11 on the
extent of 5BP crosslinking around WI-38 scratches is shown in
Figure 3; from these data, its MIC was estimated to lie between
6.25 and 12.5 mM. The MIC values of different inhibitors are
compared in Table 2 (see also Figures S2 and S3). Whereas
the most potent inhibitors (e.g., 6, 11, 14, and 16) completelyChemistry & Biology 18,blocked TG2 activity around the wound at 3.1–6.25 mM, the
less potent inhibitor 15 (kinh/KI = 6.1 mM
1 min1) only showed
partial inhibition at 25 mM.
The above cell culture measurements verified that the biolog-
ical potencies of the most active azido-DHI inhibitor (6) and the
most active alkynyl-DHI inhibitors (11 and 12) were comparable
to the benchmark DHI inhibitor of human TG2 (16) identified to
date (Watts et al., 2006). This in turn encouraged us to develop58–66, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 61
Table 2. Titration of DHI Inhibitors against TG2 in a Fibroblast
Wound Model
Each value is a representative of three or more scratches. See Figures S2
and S3.
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Tools for Visualizing Transglutaminase Activityprocedures for visualizing inhibitor-bound TG2 in biological
samples, as described below. Future improvements to these
compounds will focus on improving their water solubility and
rendering them resistant to chymotrypsin-catalyzed hydrolysis.
Both properties would be necessary for chronic oral administra-
tion in animal studies directed at elucidating TG2 regulatory
mechanisms in the small intestine and can be achieved by incor-
porating alternative amino acid residues or isosteres in place of
5-fluorotryptophan in compounds 6 and 11.Labeling and Visualization of Catalytically Active TG2
In principle the alkyne and azide groups incorporated into DHI
inhibitors can be used as handles to selectively visualize the loca-
tion of TG2 protein that is transiently activated in a biological
sample.To test thishypothesis, alkynyl-inhibitedTG2waschemo-
selectively ligated to an azide-tagged biotin or fluorophore mole-62 Chemistry & Biology 18, 58–66, January 28, 2011 ª2011 Elseviercule via aCu1-catalyzed alkyne-azide [3+2] cycloaddition reaction
(Figure 1). Initial experiments were performed with recombinant
TG2 protein activated with Ca+2 or inhibited with GTP. The
proteins were resolved by gel electrophoresis and visualized by
western blotting using neutravidin-linked horseradish peroxidase.
Catalytically active TG2 treated with 12 can be efficiently conju-
gated with a suitable azide partner molecule and subsequently
visualized in a dose-dependent manner (Figure 4, lanes 1–4).
The limit ofdetectionofactiveTG2by thiswesternblottingmethod
was below 1 mg. GTP-bound, catalytically inactive TG2 was not
labeled and, therefore, not visualized (Figure 4, lanes 5–8).
To investigate the utility of this method for visualizing catalyt-
ically active TG2 in biological systems, we performed fluores-
cence microscopy on scratched WI-38 fibroblast cultures
that had been incubated with two representative alkynyl-DHI
inhibitors, 11 and 12. In both cases, cells were extensively
washed to remove excess inhibitor, fixed with paraformalde-
hyde (PFA), permeabilized with 0.1% Triton X-100, washed
again, and subjected to the [3+2] cycloaddition reaction with
biotin azide TG2 (active + inactive). The biotin conjugate was
visualized by exposing fixed cultures to streptavidin conju-
gated with Alexa Fluor 555. The scratch was visualized with
rabbit anti-fibronectin antibody, followed by exposure to an
Alexa Fluor 488-conjugated goat anti-rabbit IgG secondary
antibody.
Analogous to experiments with 5BP (see, for example, Fig-
ure 3), a strong red fluorescence signal was observed around
the scratch in samples treated with inhibitors and reacted with
biotin azide (Figure 5; Figure S4), corresponding to catalytically
active TG2. As negative controls, DMSO vehicle and two
substantially weaker inhibitors, 17 and 18 (Table 1), were evalu-
ated. These compounds, which are diastereomeric analogs of 11
and 12, respectively, were used because earlier work had shown
that TG2 specificity was strongly dependent upon the stereo-
chemistry of the chiral center in the dihydroisoxazole ring.
Scratches treated with 17 and 18 resulted in no red fluorescence
around the scratch (Figure 5; Figure S4).
Two other observations were made during the course of these
studies with WI-38 fibroblasts. First, the signal-to-noise was
significantly superior in scratches reacted with biotin azide as
compared to rhodamine azide (Figure S5). The reason for this
difference was not investigated. Second, 5BP yields a distinctly
different labeling pattern around the fibroblast scratch than theFigure 4. Visualization of Recombinant TG2 with
Alkynyl-DHI Inhibitor 12
Recombinant TG2 was inhibited with 12 in the presence of
CaCl2 (5 mM) or GTP (500 mM) and MgCl2 (1 mM). The re-
sulting mixture was reacted with biotin-azide, resolved by
SDS-PAGE, and detected by western blotting with neutra-
vidin-HRP. Lane 1 shows TG2 (0.2 mg) + Ca2+ + 12; lane 2,
TG2 (0.4 mg) + Ca2+ + 12; lane 3, TG2 (1 mg) + Ca2+ + 12;
lane 4, TG2 (4 mg) + Ca2+ + 12; lane 5, TG2 (0.4 mg) +
GTP/MgCl2 + 12; lane 6, TG2 (1 mg) + GTP/MgCl2 + 12;
lane 7, TG2 (1 mg) + GTP/MgCl2 + 12; and lane 8, TG2
(4 mg) + GTP/MgCl2 + 12.
Ltd All rights reserved
Figure 5. Visualization of Catalytically
Active TG2 in a Scratched WI-38 Fibroblast
Culture
TG2 activity was visualized after scratching
confluent WI-38 monolayers in the presence of
50 mM 11 (A–F) or 17 (G–I) for 1 hr. Cells were
then fixed, permeabilized, reacted with biotin
azide followed by streptavidin-Alexa Fluor 555
conjugates (red), and imaged by epifluorescence
microscopy through a 103 objective.
(A, D, and G) Rabbit anti-fibronectin antibody, fol-
lowed by a secondary antibody labeled with Alexa
Fluor 488, was used to visualize fibronectin on the
WI-38 monolayers.
(B, E, and H) Catalytically active TG2 was visual-
ized by coupling the alkynyl-DHI inhibitor to biotin
azide.
(C, F, and I) Overlays of the left and middle image
pairs are shown in the right column. Scale bar
represents 200 mm and applies to all panels.
See Figures S4 and S5.
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red and green signals is excellent in Figure 3A, the two colors
are proximal but clearly discernable in Figure 5E. Presumably,
this is due to subtle differences in the distribution of catalytically
active TG2 (i.e., the target of the clickable inhibitor) and its
substrates (principally fibronectin, which is the target of 5BP) in
the vicinity of the scratch.
DISCUSSION
Human TG2 catalyzes transamidation and deamidation reac-
tions that are believed to contribute to a variety of physiological
processes as well as to the pathogenesis of several diseases.
Therefore, understanding the mechanisms responsible for
spatiotemporal regulation of TG2 activity could have important
implications for human biology and disease. However, because
the protein is abundantly expressed in most organs and tissues,
most mechanisms of interest are allosteric in nature, and
conventional molecular biology approaches are not applicable.
Consequently, new tools are needed to visualize rapid, tissue-
specific transitions of TG2 from a catalytically inactive to an
active state (or vice versa). Because TG2 is localized in multiple
intracellular compartments as well as the extracellular environ-
ment, the ideal tools should also be able to resolve the subcel-
lular location of the target protein. Here, we have described
a new class of small molecule reagents that are well suitedChemistry & Biology 18, 58–66, January 28, 201for such a task. As shown, our clickable
TG2 inhibitors can visualize the active
enzyme in a manner that is only limited
by the resolution of optical microscopy.
Specifically, we have shown that com-
pounds 11 and 12 can be used to visu-
alize the burst of TG2 catalytic activity
that rapidly appears at the scratch
boundary of a WI-38 fibroblast cell
culture system. Although the fibroblast
scratch assay mimics a pathological
rather than a physiological state, its utilityfor interrogating the allosteric transition of TG2 from an inactive
to an active state has been established (Nicholas et al., 2003;
Siegel et al., 2008). Our method has two principal advantages
over previous studies that visualized transiently activated TG2
around scratched cells using amine substrates such as 5BP.
First, whereas the use of amines only enables detection of
TG2 substrates (principally fibronectin) that have undergone
modification by catalytically active enzyme, our new method
enables visualization of the activated enzyme itself. As illus-
trated by the differences between the labeling patterns around
scratches in Figures 3 and 5, these differences may prove
significant in further investigations of TG2 biology, especially
in situations where subcellular resolution of the active enzyme
is desired. Second, because the specificity of transglutami-
nases for their electrophilic (glutamine-bearing) substrates is
considerably higher than for nucleophilic (amine-bearing)
substrates, the development of isozyme-specific clickable DHI
inhibitors should be feasible.
Pending verification of their in vivo stability, several important
biological and medical problems could be addressed with click-
able DHI inhibitors such as 11 and 12. In metastatic cancers,
TG2 is believed to play a crucial role in cell migration and has
been shown to localize primarily at the leading edge of
migrating cells (Antonyak et al., 2009). However, the relative
importance of its catalytic versus signaling activity is unclear.
For example the catalytically inactive C277S mutant of TG2 is1 ª2011 Elsevier Ltd All rights reserved 63
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motility (Balklava et al., 2002). Visualizing the precise location(s)
of catalytically active TG2 over the course of a nascent and
metastasizing tumor could shed important light on the role of
protein crosslinking in cancer. In celiac sprue the pathogenic
role of catalytic TG2 is well established; however, the precise
location at which catalytically active TG2 encounters immuno-
toxic gluten peptides remains a topic of controversy. Again,
small molecule probes that can highlight the distribution of
active enzyme in normal versus inflamed intestinal mucosa
could be invaluable. More fundamentally, biochemical and
structural biological investigations have demonstrated that
TG2 undergoes allosteric changes between at least three
distinct conformational states, as summarized in the scheme
below:
Tools that can distinguish between the Ca+2-bound active
state versus the GTP-bound or disulfide-bonded inactive states
could greatly facilitate a deeper understanding of the dynamics
of this multifunctional protein in biological systems.
In conclusion, we also note that our lead clickable inhibitors
reported here could be further improved with respect to several
characteristics. First, they have relatively low solubility in
aqueous buffers. The efficiency of labeling TG2-bound inhibitors
via [3+2] cycloaddition could also be improved by varying the
spacer length between the alkyne and the benzyl groups. Last,
but not least, the reactivity of these inhibitors with other mamma-
lian transglutaminases could be further engineered in order to
develop probes with orthogonal specificity for individual
isozymes of this protein family.SIGNIFICANCE
We have developed nonradioactive chemical probes for de-
tecting and imaging catalytically active transglutaminase
2 (TG2) in mammalian cells and tissues. A series of electro-
philic dihydroisoxazole compounds have been engineered
with alkyne and azide groups that can be further modified
by ‘‘clickchemistry’’ (Cu1-catalyzedalkynyl-azide [3+2]cyclo-
addition). These compounds have high specificity for the TG2
active site and undergo an irreversible reactionwith the cata-
lytically active cysteine residue. The biological utility of these
mechanism-based irreversible inhibitors is demonstrated by
theirability tovisualizetransientlyactivatedTG2 inafibroblast
scratch assay. These probes should be broadly useful in
elucidating mechanisms responsible for allosteric regulation
of this multifunctional protein in cell biology, mammalian
development, as well as a variety of human diseases.EXPERIMENTAL PROCEDURES
Cell Culture and Antibodies
WI-38 fibroblasts were grown in minimum essential media (GIBCO; 11095)
containing L-glutamine, Earle’s salts, nonessential amino acids (GIBCO;
11140), sodium pyruvate (GIBCO; 11360), 10% fetal bovine serum (FBS)64 Chemistry & Biology 18, 58–66, January 28, 2011 ª2011 Elsevier(Atlanta Biologicals), and 100 U/ml penicillin + 100 mg/ml streptomycin
(GIBCO; 15140). Cells were typically grown to 80%–90% confluency before
treating with trypsin-EDTA (GIBCO; 15400) and splitting. All cells were grown
in a humidified incubator at 37C, 5% CO2. The antibodies used were anti-
fibronectin antibody produced in Rabbit (Sigma-Aldrich; F3648), Alexa Fluor
488 goat anti-rabbit IgG (H-L) antibody (Invitrogen; A-11008), and Alexa Fluor
555-labeled streptavidin (Invitrogen; S-21381).
Synthesis of Alkynyl- and Azido-DHI Inhibitors
Compounds 3–18were synthesized as previously reported (Watts et al., 2006).
Briefly, 4-ethynylbenzyl alcohol was reacted with p-nitrophenyl chloroformate
in methylene chloride and N-methylmorpholine to give a carbonate of
4-ethynyl benzyl and p-nitrophenol after purification by flash chromatography.
The carbonate was reacted with the methyl ester of the amino acid in DMF and
N-methylmorpholine to give 4-ethynyl benzyl carbamate protected amino acid
methyl ester. Methyl ester hydrolysis, followed by EDCI coupling of resulting
acid to the (S)-isomer of the halo-dihydroisoxazole, gave the indicated
compound as a final product after flash chromatography purification. The
azido-DHI compounds were synthesized in similar fashion.
TG2 Inhibition Assays
Recombinant human TG2 was expressed in E. coli and purified to >90%
homogeneity as described previously(Choi et al., 2005). The potency of indi-
vidual DHI inhibitors was assayed in a reaction mixture containing 200 mM
MOPS (pH 7.2), 5 mM CaCl2, 1 mM EDTA, 10 mM a-ketoglutarate, 18 U/ml
glutamate dehydrogenase, 0.4 mM NADH, 3.3% (v/v) DMSO, 0.5 mM TG2,
and 10, 20, and 30 mM Cbz-Gln-Gly (KM = 6.28 mM, kcat. = 37 min
1). The
concentration of each inhibitor was varied from 0.001 to 0.3 mM. The reaction
was initiated by adding TG2, and the consumption of NADH was monitored by
UV spectroscopy (340 nm, 3 = 6220 cm1 M1). Kinetic parameters were
obtained by plotting the reaction progress curves against theoretical equa-
tions for irreversible enzyme inhibition.
Labeling and Visualization of TG2 with Clickable Inhibitors
TG2 protein was subjected to the probe labeling in 50 ml volume reaction con-
taining a final concentration of 2 mM of 12, and 5 mM CaCl2 or 500 mM GTP/
1 mM MgCl2 in 100 mM Tris HCl (pH 7.2) for 1 hr at RT. Then, 2 mM of biotin
azide was added, 1 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP;
Sigma-Aldrich) dissolved in water, 0.2 mM tris[(1-benzyl-1H-1,2,3-triazole-
4-yl)methyl amine (TBTA; Sigma-Aldrich) dissolved in DMSO/tert-butanol
(20%/80%), and 1 mM CuSO4 in PBS. The reaction was quenched with 23
loading buffer. Samples were resolved by SDS-PAGE using 4%–20% Tris-
glycine gels and transferred onto a nitrocellulose membrane. The membrane
was blocked with PBS, 0.1% Tween 20 (PBST), and 5% nonfat dried milk
for 1 hr at RT. The membrane was washed three times with PBST (5 min
each) and incubated with neutravidin-horseradish peroxidase (Invitrogen;
1:200 in 5% nonfat driedmilk) for 1 hr at RT. Themembrane was washed again
with PBST three times (10 min each) and developed according to manufac-
turer’s recommendation (Amersham Biosciences).
Detection of TG2 Activity in Fibroblast Scratch Assays Using 5BP
WI-38 fibroblasts were plated in an 8-well chamber glass slide at 23 105 cells/
well and grown for 3 days with medium change every 2 days. Small scratches
were made in the monolayer with 0.1–10 ml pipette tip, and the cells were
incubated with 5BP for 1 hr at 37C, 5% CO2. To capture the highest TG2
activity around the wound, we performed titration assays using 50, 100, 150,
and 300 mM 5BP; the best results were obtained at 300 mM 5BP. To quantify
TG2 inhibition in cultured cells, inhibitors 3–18 were added at the indicated
concentrations to the culture media for 10–15 min. An equal amount of vehicle
(DMSO) was added to themedia of control cells at 37C. Then, 5BPwas added
at a final concentration 300 mM and incubated for an additional 1 hr at 37C,
5% CO2. The cells were washed three times with PBS and fixed with 20C
methanol for 10 min. Fixed cells were washed again with PBS twice for
5 min, blocked with 1% BSA in PBS for 15 min at room temperature, and
washed twice more with PBS. Anti-fibronectin antibody produced in Rabbit
(F3648; Sigma-Aldrich) was diluted 1:500 in blocking buffer and incubated
for 1 hr at RT. Cells were washed three times with PBS and incubated with
Alexa Fluor 488 goat anti-rabbit IgG (H+L) (A-11034; Invitrogen) and Alexa FluorLtd All rights reserved
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washes with PBS, 300 ml PBS was added onto each sample before visualiza-
tion via fluorescence microscopy. Note that Factor XIII, another ubiquitous
member of the transglutaminase family, is not expressed in WI-38 fibroblasts
(data not shown).Detection of TG2 Activity in Fibroblast Scratch Assays Using
Clickable Inhibitors
Following WI-38 fibroblast cell growth and scratching as above, compounds
11 and 12were added to living cells for 10–15 min at 50 mM final concentration
at 37C, 5% CO2. Control cells were incubated with 300 mM 5BP and vehicle
(DMSO). Cells were washed three times with PBS to remove excess
compounds and fixed with 4% PFA for 10 min at RT. Cells were then permea-
bilized with PBS/0.1% Triton X-100 for 1–2 min at RT, washed extensively with
PBS, and subjected to the [3+2] cycloaddition reaction at RT for 1 hr in 175 ml
solution containing 1 mM biotin azide, 1 mM TCEP dissolved in water, and
1 mM CuSO4 in PBS. The labeled samples were rinsed extensively with PBS
and blocked in PBS/5% BSA for 45 min at RT. To visualize the fibronectin
protein, samples were treated with rabbit anti-fibronectin for 1 hr at RT in
PBS/5%BSA, then washed three times with PBS, and further stained with
the goat anti-Rabbit Alexa Fluor 488-conjugated secondary antibody for
45 min in PBS/5% BSA at RT. After three further washes, 300 ml of PBS was
added onto the cells for visualization via microscopy. Fluorescent images
were captured in an upright Zeiss microscope.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at doi:10.1016/j.
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